Functional POLE Variant Classification for Immunotherapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Historical classification of POLE variants has been anecdotal and based on limited evidence, lacking a comprehensive framework for accurate pathogenicity assignment, which affects the diagnosis and clinical management of tumors with pathogenic POLE variants.
Innovation Solution
A functional readout-based framework is developed to classify POLE variants by leveraging multiple features of the ultramutated tumor phenotype, including POLE exonuclease deficiency and microsatellite instability, enabling nuanced pathogenicity assignment and treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If historical anecdotal classification methods are used for POLE variants, then the classification process is simple and quick, but the accuracy and reliability of pathogenicity assignment is poor
Solution Approach 1:
The classification framework segments the POLE variant assessment into distinct functional domains: (1) variant detection, (2) functional impact assessment through exonuclease deficiency analysis, (3) phenotypic correlation with ultramutated tumor characteristics, and (4) clinical implication determination. This segmentation allows systematic evaluation of multiple features without overwhelming complexity, improving accuracy while maintaining manageable framework structure.
Solution Approach 2:
The framework integrates multiple functional readouts and phenotypic features into a unified classification system that can assess both recurrent and rare POLE variants across different cancer types. The same multi-feature framework applies universally to diverse tumor contexts, enabling consistent pathogenicity assignment while adapting to specific clinical scenarios through the integrated assessment of multiple parameters.
2Reliability
If limited evidence-based classification is used, then the diagnostic process is faster and less resource-intensive, but the reliability of diagnosis and clinical management is compromised
Solution Approach 1:
The framework performs preliminary functional assessment of POLE variants by evaluating exonuclease deficiency and predicted phenotypic effects before final pathogenicity assignment. This preliminary functional readout establishes a foundation for reliable diagnosis that can be efficiently integrated into clinical workflows, reducing the need for time-consuming additional testing while ensuring diagnostic accuracy through systematic evaluation of multiple features.
3Measurement precision
If comprehensive multi-feature classification framework is implemented, then the pathogenicity assignment accuracy is improved, but the complexity of variant analysis and diagnostic workflow increases
Solution Approach 1:
The framework introduces functional readouts as intermediary measures that bridge the gap between raw variant data and clinical interpretation. By assessing exonuclease deficiency and correlating with phenotypic features like ultramutated tumor characteristics, the framework creates intermediate classification layers that simplify the overall analysis process while maintaining high precision. These intermediary functional assessments make the complex multi-feature evaluation more manageable and interpretable.
Data Source
AI summary
Methods are described for identifying and/or treating patients who may benefit from immunotherapy based on classification of POLE variants identified using genomic profiling data. In some instances, for example, the disclosed methods of treating a subject having a cancer comprise: acquiring a genomic profile based on a sample from the subject, wherein the genomic profile is indicative of: (i) the presence of a pathogenic POLE (pPOLE) variant, or (ii) the presence of a pathogenic POLE (pPOLE) variant and a microsatellite instability (MSI) status of MSI-high; and responsive to an indication that a pathogenic POLE (pPOLE) variant is present, with or without an indication of MSI-high status, administering an anti-cancer therapy to the subject; thereby treating the subject.